Keywords: Roche, Genentech, Curis, Vismodegib, Basal cell carcinoma, USA, FDA, Priority review
FDA priority review for Roche/Genentech’s vismodegib for skin cancer
Article | 10 November 2011
The US Food and Drug Administration has accepted and filed Swiss drug major Roche (ROG: SIX) subsidiary Genentech’s ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
